References
- Jacob MC, Chaperot L, Mossuz P, et al. CD41 CD561 lineage negative malignancies: a new entity developed from malignant early plasmacytoid dendritic cells. Haematologica. 2003;88:941–955.
- Pagano L, Valentini CG, Pulsoni A, et al. (Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study. Haematologica. 2013;98:239–246.
- Petrella T, Bagot M, Willemze R, et al. Blastic NK-cell lymphomas (agranular CD4 + CD56+ hematodermic neoplasms): a review. Am J Clin Pathol. 2005;123:662–675.
- Reimer P, Rudiger T, Kraemer D, et al. What is CD4 + CD56+ malignancy and how should it be treated? Bone Marrow Transplant. 2003;32:637–646.
- Aoki T, Suzuki R, Kuwatsuka Y, et al. Long-term survival following autologous and allogeneic stem cell transplantation for blastic plasmacytoid dendritic cell neoplasm. Blood. 2014;125:3559–3562.
- Roos-Weil D, Dietrich S, Boumendil A, et al. Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blodo and Marrow Transplantation. Blood. 2013;121:440–446.
- Gurion R, Vidal L, Gafter-Gvili A, et al. 5-Azacitidine prolongs overall survival in patients with myelodysplastic syndrome – a systematic review and meta-analysis. Haematologica. 2010;95:303–310.
- Jegalian AG, Buxbaum NP, Facchetti F, et al. Blastic plasmacytoid dendritic cell neoplasm in children: diagnostic features and clinical implications. Haematologica. 2010;95:1873–1879.
- Dalle S, Beylot-Barry M, Bagot M, et al. Blastic plasmacytoid dendritic cell neoplasm: is transplantation the treatment of choice? Br J Dermatol. 2010;162:74–79.
- Atalay F, Demirci GT, Bayramgürler D, et al. Blastic plasmacytoid dendritic cell neoplasm: skin and bone marrow infiltration of three cases and the review of the literature. Indian J Hematol Blood Transfusion. 2015;31:302–306.
- Laribi K, Denizon N, Ghnaya H, et al. Blastic plasmacytoid dendritic cell neoplasm: the first report of two cases treated by 5-azacytidine. Eur J Haematol. 2014;93:81–85.
- Riaz W, Zhang L, Horna P, et al. Blastic plasmacytoid dendritic cell neoplasm: update on molecular biology, diagnosis, and therapy. Blastic plasmacytoid dendritic cell neoplasm: update on molecular biology, diagnosis, and therapy. 2014;21:279–289.
- Wiesner T, Obenauf AC, Cota C, et al. Alterations of the cell-cycle inhibitors p27(KIP1) and p16(INK4a) are frequent in blastic plasmacytoid dendritic cell neoplasms. J Invest Dermatol. 2010;130:1152–1157.
- Lucioni M, Novara F, Fiandrino G, et al. Twenty-one cases of blastic plasmacytoid dendritic cell neoplasm: focus on biallelic locus 9p21.3 deletion. Blood. 2011;118:4591–4594.
- Sapienza MR, Fuligni F, Agostinelli C, et al. Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to NF-KB pathway inhibition. Leukemia. 2014;28:1606–1616.